AOD-9604 vs semaglutide: what the human trial data actually shows

Last updated 2026-07-25

What is AOD-9604 and how is it different from semaglutide?

AOD-9604 is a 16-amino-acid fragment of human growth hormone, built from the C-terminal region (amino acids 176-191) that researchers believed was responsible for GH's fat-metabolizing effects without touching growth or blood sugar. The idea, going back to research summarized in a 2004 review in Current Opinion in Investigational Drugs, was to isolate the lipolytic piece of the GH molecule and leave the rest behind ^[1]. It was developed by Metabolic Pharmaceuticals in Australia and studied as an obesity treatment through the mid-2000s. Semaglutide works nothing like this. It's a GLP-1 receptor agonist, a synthetic version of a gut hormone that slows stomach emptying, signals fullness to the brain, and helps regulate insulin. It's sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, all FDA-approved products you can look up directly in the Drugs@FDA database ^[2]. So the mechanisms aren't cousins. One is a fragment of a growth hormone molecule chasing a fat-burning side effect. The other is a full receptor agonist built around appetite and satiety signaling, with a drug approval to match. That difference in mechanism maps almost exactly onto the difference in how well each one is actually proven to work.

Did AOD-9604 actually work in human obesity trials?

This is the question that matters most, and the honest answer is: not clearly. AOD-9604 went through Phase II and Phase III human trials for obesity in the early-to-mid 2000s, run by Metabolic Pharmaceuticals. The trial record, as described in the pharmaceutical development literature, showed weight loss in treated groups, but the separation from placebo was not convincing enough to support approval ^[1]. That's a critical detail to sit with. A drug can show numbers that move in the right direction, average weight loss, some metabolic markers, and still fail to prove it does more than a sugar pill once you control for the trial noise. That is what happened here. The 2004 review covering AOD-9604's metabolic profile documents this pattern in the clinical program ^[1], and later overviews of the obesity drug pipeline reference AOD-9604 as one of several candidates that didn't make it through to market on efficacy grounds ^[3]. No late-stage confirmatory trial has reversed this. There's no FDA-approved indication for AOD-9604, and it doesn't appear in the Drugs@FDA database as an approved product for any use ^[2]. If a supplier or forum post tells you AOD-9604 is "in FDA trials" as if that means it's close to approval, be skeptical. It went through trials once, over a decade ago, and the efficacy signal wasn't strong enough to move forward. For a fuller breakdown of the underlying evidence and what the peptide is studied for outside the obesity trials, see the AOD-9604 peptide overview.

How strong is the human trial evidence for semaglutide?

Much stronger, and this isn't close. Semaglutide's weight-loss trials (the STEP program) enrolled thousands of participants and reported average weight loss around 15% of body weight at higher doses over roughly 68 weeks, findings that supported FDA approval of Wegovy for chronic weight management. This is public record through the FDA's own approval database, which lists Wegovy (semaglutide) as an approved product you can verify directly ^[2]. The contrast with AOD-9604 isn't about which peptide is more popular or more talked-about online. It's that semaglutide cleared the bar that AOD-9604 didn't: a large randomized trial program that separated cleanly from placebo, reviewed by a regulator, resulting in an approved drug with a label, dosing schedule, and monitored safety data. That doesn't mean semaglutide is free of downsides. GI side effects (nausea, vomiting, constipation) are common, and there are real questions about weight regain after stopping, cost of ongoing treatment, and long-term use in non-diabetic populations. But the efficacy question, does it produce meaningful fat loss beyond placebo, has been answered for semaglutide in a way it has not been answered for AOD-9604.

AOD-9604 vs semaglutide: side by side

The table makes the gap obvious. One column has an approval and a large trial program behind it. The other has a trial program that didn't clear the efficacy bar and no approval since.

Why did AOD-9604 fail to separate from placebo in trials?

Nobody has a fully settled answer, and that's an honest place to leave it. The published record from the 2004 review of AOD-9604's clinical development notes the fragment's designed rationale (isolate the lipolytic domain of GH, avoid growth and insulin effects) but the trial outcomes didn't confirm strong real-world fat-loss efficacy at the doses and durations tested ^[1]. A few possibilities show up in the broader obesity drug literature. Fragment peptides derived from larger hormones sometimes lose potency or receptor affinity when isolated from the full molecule, even when the rationale on paper looks clean. It's also possible the effect is real but small, small enough that a placebo-controlled trial with typical dropout and adherence noise can't detect it reliably. A 2006 overview of the obesity drug development pipeline lists AOD-9604 among a group of candidates that didn't advance to market for efficacy reasons, without singling out a specific mechanistic failure ^[3]. What we don't have is a large, recent, independent trial that revisits AOD-9604 with modern trial design and puts the question to rest either way. Until that exists, the honest label for AOD-9604's obesity claim is "not supported by the human trial record we have," not "disproven forever." Those are different claims and it matters which one you make.

Is AOD-9604 legal to buy, and how does that compare to semaglutide?

Semaglutide is a prescription drug. You get it through a licensed prescriber and a pharmacy, under the normal drug distribution and dispensing rules that apply to any FDA-approved medication. AOD-9604 is different. It's not FDA-approved for human use, and it does not appear on either the 503A bulk drug substances list for traditional compounding or the 503B list for outsourcing facility compounding, the two lists FDA maintains under 21 CFR 216.23 and 216.24 that determine what compounders can legally use ^[4][5]. Under 21 U.S.C. 353a, compounded drugs get certain exemptions from FDA approval requirements, but only when compounding pharmacies use substances on FDA's permitted lists, and AOD-9604 isn't on them ^[7]. FDA also maintains guidance specifically on bulk substances used in 503A compounding, and a nominated substances list, neither of which currently includes AOD-9604 as an approved bulk for human compounding ^[8][9]. Practically, this means AOD-9604 is sold as a research chemical, labeled "not for human consumption," and anyone selling it framed as a weight-loss product intended for human use is misrepresenting its regulatory status under 21 CFR 201.128's definition of intended use ^[10]. If you're weighing where to get it despite that limitation, read best place to buy AOD-9604 and AOD-9604 peptide for sale for what "provider-reviewed" actually means in this space, because sourcing quality varies enormously and most of the market is unregulated.

Does AOD-9604 show up on anti-doping tests, and does that matter for the comparison?

This is a narrower but genuinely interesting piece of the record. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the WADA hGH isoform immunoassay, meaning it doesn't trigger a positive result on the standard test used to detect growth hormone doping ^[6]. That's a specific analytical finding, not a statement about safety or effectiveness for fat loss. The anti-doping and forensic literature has spent more attention on detecting AOD-9604 itself than on proving it works. A 2014 review in Expert Review of Proteomics on detecting peptide drugs in sports doping covers AOD-9604 as an analyte of interest for testing labs ^[8]. Separately, a 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on detecting emerging and non-approved drugs in doping controls, and a 2016 method in the Journal of Separation Science for screening small peptides under 2 kDa by direct urine injection, both address how labs try to catch AOD-9604 use in athletes ^[10][9]. Semaglutide isn't part of this conversation in the same way. It's not a growth hormone analog and isn't pursued through the hGH isoform assay. If you're asking which one carries doping-detection risk in a tested sport, that's a separate question from which one helps you lose fat, and the two shouldn't get mixed up. AOD-9604's testing profile tells you about detectability, not efficacy.

What does AOD-9604 get used for now, if not proven for weight loss?

Most of the current research interest in AOD-9604 has drifted away from obesity and toward musculoskeletal and orthopedic applications. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedics discusses AOD-9604 among peptides being examined for joint and tissue applications, separate from its original fat-loss rationale ^[11]. A companion 2026 review in Sports Medicine on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance covers AOD-9604 in this same context, evaluating it alongside other peptides used off-label in sports medicine and recovery settings ^[12]. Neither of these papers revisits or confirms the original obesity claim; they're looking at a different application entirely. This matters for anyone shopping AOD-9604 specifically for fat loss. The most recent serious research attention on this molecule isn't rebuilding the weight-loss case. It's exploring whether the peptide has value in a completely different area. If you came here looking for confirmation that new studies back up the fat-burning claim, that confirmation doesn't exist in the current literature.

How does AOD-9604 compare to other GH-derived peptides like tesamorelin?

Tesamorelin is a better comparison point than semaglutide in one specific way: it's also GH-pathway-derived, but unlike AOD-9604 it has an actual FDA approval, for HIV-associated lipodystrophy (reduction of excess abdominal fat in that specific patient population). That's a narrow, specific approval, not a general weight-loss green light, but it's still a real regulatory outcome AOD-9604 never achieved. The mechanism differs too: tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the body's own GH production, while AOD-9604 is a GH fragment that was supposed to skip the GH-release step entirely and act directly on fat metabolism. Both were built around the same broad idea, that GH pathways matter for fat regulation, but tesamorelin has trial data and an approval behind it in its lane, and AOD-9604 does not. For a full breakdown of that comparison, mechanism differences, trial data, and what tesamorelin's approval actually covers, see AOD-9604 vs tesamorelin.

If the trial data is weak, why do people still use AOD-9604 for fat loss?

A mix of reasons, and none of them are "because new trials proved it works." Price is one: AOD-9604 is cheap relative to prescription GLP-1 drugs, and it's sold without a prescription through research-chemical channels, which lowers the barrier to trying it regardless of the evidence gap. Anecdote is another driver. Forums and social media are full of self-reported results, and self-reported fat loss while dieting and training is notoriously hard to attribute to any one input, especially a peptide with no confirmed mechanism of action at the doses typically self-administered. The original theoretical rationale, that this exact fragment isolates GH's fat-burning effect, is genuinely elegant on paper. Elegant biology doesn't guarantee clinical results, and this is one of the clearer cases of that gap in the peptide space. If you're set on trying it anyway, understanding dosing and timing correctly matters more given the uncertain efficacy, not less; see when to take AOD-9604 peptide and how to reconstitute AOD-9604 for the practical mechanics. But go in knowing what the trial record actually says, not what the marketing implies.

So which one should you actually use for fat loss?

If your goal is fat loss with real trial evidence behind it, semaglutide is the answer, full stop. It has FDA approval, large randomized trials, and a weight-loss effect size (around 15% of body weight in the STEP trials) that clearly separated from placebo ^[2]. That comes with a prescription requirement, real side effects, and a cost that's much higher than a research peptide, but the efficacy question is settled in a way AOD-9604's is not. AOD-9604 doesn't have that evidence. Its obesity trials didn't produce a convincing separation from placebo ^[1], it has no FDA approval for any use ^[2], and current research interest has moved toward orthopedic and musculoskeletal applications rather than confirming the original fat-loss claim ^[11][12]. If you're going to explore it anyway, understanding what it actually is matters, and AOD-9604 peptide is the honest starting point on the mechanism and evidence. Where AOD-9604 Co adds value here isn't in claiming this peptide is proven for weight loss, because it isn't. It's in pointing to a provider-reviewed sourcing route with a named fulfilling pharmacy partner, so if you're going to use a research peptide despite the unclear efficacy data, at least the product quality and handling side is accounted for. That's a sourcing decision, not a substitute for the missing trial evidence.

Frequently asked questions

Is AOD-9604 as effective as semaglutide for weight loss?

No. Semaglutide's trials showed roughly 15% average body weight loss versus placebo, evidence strong enough for FDA approval ^[12]. AOD-9604's obesity trials did not show a convincing separation from placebo ^[1], and it has no approval for weight loss. The evidence bases aren't comparable.

Has AOD-9604 been FDA approved for weight loss?

No. AOD-9604 does not appear in the FDA's Drugs@FDA database as an approved product for any use ^[12]. It went through Phase II/III obesity trials in the mid-2000s that did not produce results strong enough to support approval ^[1].

What is the mechanism difference between AOD-9604 and semaglutide?

AOD-9604 is a fragment of human growth hormone (amino acids 176-191) theorized to isolate GH's fat-metabolizing effect ^[1]. Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. They act through entirely different biological pathways.

Can you buy AOD-9604 legally like semaglutide?

Semaglutide requires a prescription and is dispensed by licensed pharmacies. AOD-9604 is not on FDA's 503A or 503B bulk drug substance lists for compounding ^[7][8], so it's sold as a research chemical, not a prescribed medication, under a different and much less regulated pathway.

Does AOD-9604 show up on a growth hormone doping test?

A 2013 study found AOD-9604 does not influence the WADA hGH isoform immunoassay, meaning it doesn't trigger that specific test ^[4]. This is a detection finding, not evidence about safety or fat-loss effectiveness, and separate labs use other methods to detect the peptide directly.

Why did AOD-9604 fail its obesity trials?

The exact mechanistic reason isn't fully settled in the literature. Published trial summaries describe weight loss that didn't separate convincingly from placebo ^[1], and later obesity-pipeline reviews list it among candidates that didn't reach market on efficacy grounds ^[5], without pinpointing one specific cause.

Is semaglutide safer than AOD-9604?

Semaglutide has an established safety and side effect profile from large FDA-reviewed trials (GI symptoms being most common). AOD-9604 lacks that scale of scrutiny for long-term human safety, since its obesity program didn't advance, so its safety data outside research settings is much thinner.

What is AOD-9604 currently being studied for, if not obesity?

Recent 2026 reviews cover AOD-9604 in orthopedic and musculoskeletal contexts, alongside other peptides used in sports medicine and recovery ^[2][3]. This is a different research direction from the original fat-loss rationale, and it doesn't reconfirm the obesity claim.

Is AOD-9604 a growth hormone releasing peptide like tesamorelin?

No. Tesamorelin is a GHRH analog that stimulates the body's own GH release and has FDA approval for HIV-associated lipodystrophy. AOD-9604 is a GH fragment designed to skip GH release and act directly, but without an approval behind it. See the full comparison at AOD-9604 vs tesamorelin.

How much cheaper is AOD-9604 than semaglutide?

AOD-9604 is sold as an unregulated research chemical at prices far below prescription semaglutide, which runs into the hundreds of dollars per month without insurance coverage. But price comparisons don't account for the missing efficacy evidence behind AOD-9604's obesity claim ^[1].

Can AOD-9604 be combined with semaglutide?

There's no published human trial data on combining AOD-9604 with semaglutide specifically. Given AOD-9604's own obesity trial results didn't separate from placebo ^[1], any added benefit from stacking it with a proven GLP-1 drug is speculative and unsupported by current research.

Does AOD-9604 raise blood sugar or affect insulin like growth hormone does?

The original design rationale for AOD-9604 was to isolate GH's fat-metabolizing region while avoiding the growth and insulin-affecting properties of full-length GH ^[1]. Whether this holds cleanly at typical self-administered doses in unregulated research use hasn't been confirmed by a large, modern controlled trial.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604's clinical obesity trial program showed weight loss that did not separate convincingly from placebo
2. PubMed, JAAOS Global Research & Reviews (2026): Recent research on AOD-9604 has shifted toward orthopedic and musculoskeletal applications
3. PubMed, Sports Medicine (2026): AOD-9604 is reviewed alongside other peptides used off-label in musculoskeletal injury and athletic performance contexts
4. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping
5. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 is listed among obesity drug candidates that did not advance to market on efficacy grounds
6. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical methods have been developed to detect emerging and non-approved peptide drugs like AOD-9604 in doping controls
7. eCFR, 21 CFR 216.23 (503A Bulks List): AOD-9604 is not on FDA's 503A bulk drug substances list for traditional pharmacy compounding
8. eCFR, 21 CFR 216.24 (503B Bulks List): AOD-9604 is not on FDA's 503B bulk drug substances list for outsourcing facility compounding
9. Cornell Law, 21 U.S.C. 353a: Compounded drugs receive certain FDA approval exemptions only when compounders use substances on FDA's permitted bulk lists
10. PubMed, Expert Review of Proteomics (2014): AOD-9604 is covered as an analyte of interest in sports doping detection literature
11. PubMed, Journal of Separation Science (2016): A direct urine injection and ion mobility mass spectrometry method was developed to screen small peptides including AOD-9604
12. FDA, Drugs@FDA database: Semaglutide products (Wegovy, Ozempic) are FDA-approved; AOD-9604 does not appear as an approved product for any use